CAPR — Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 160
- Website: https://www.capricor.com
Latest SEC filings for CAPR
- 8-K — 2026-08-24
- 10-Q — 2026-08-14
- 8-K — 2026-08-13
- SCHEDULE 13G — 2026-08-07
- 8-K — 2026-07-30
- 8-K — 2026-07-29
- 8-K — 2026-07-14
- 8-K — 2026-06-26
- 8-K — 2026-06-08
- 10-Q — 2026-05-13
Latest CAPR news
- — Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript (seekingalpha.com)
- — Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears (marketbeat.com)
- — Capricor drops as deramiocel OLE data fails to quell regulatory concerns (seekingalpha_market)
- — Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
- — Inflation Breather Could Help Stocks Finish Q3 Strong
- — Capricor jumps as study shows longer-term effects of deramiocel (seekingalpha_market)
- — CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026 (businesswire.com)
- — Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Capricor Therapeutics, Inc. Lawsuit - CAPR (globenewswire.com)
- — CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
- — CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law (prnewswire_financial)
Educational tool only — not investment advice.